Ph-responsive rutin-loaded zeolitic imidazolate framework-8 nanoparticles for targeted neuroprotection in parkinson’s disease

IN597467BActive Publication Date: 2026-07-30INDIAN INST OF TECH BANARAS HINDU UNIV VARANASI
0 Cites 0 Cited by

Patent Information

Application Number
IN202511067981
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2025-07-16
Publication Date
2026-07-30
Estimated Expiration
2045-07-16

AI Technical Summary

Technical Problem

Current therapies for Parkinson's disease, such as levodopa and dopamine agonists, provide symptomatic relief but do not prevent neurodegeneration, and are limited by rutin's poor solubility, low membrane permeability, rapid metabolic degradation, and the blood-brain barrier, leading to systemic distribution and subtherapeutic drug levels in the brain.

Method used

A pH-responsive nanoparticle-based drug delivery system using rutin-loaded zeolitic imidazolate framework-8 (ZIF-8) nanoparticles that encapsulates rutin via electrostatic interaction, allowing stable transport across the blood-brain barrier and controlled release in acidic neurodegenerative regions.

Benefits of technology

Enhances rutin's solubility and bioavailability, facilitates targeted neuroprotection in Parkinson's disease by delivering rutin specifically to affected brain regions, reducing systemic side effects and improving therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to a pH-responsive nanoparticle-based drug delivery composition for targeted neuroprotection in Parkinson’s disease. The composition comprises rutin, a naturally occurring flavonoid compound with antioxidant and neuroprotective properties, encapsulated within zeolitic imidazolate framework-8 (ZIF-8) nanoparticles. The ZIF-8 framework is formed by coordination of zinc ions and 2-methylimidazole, providing a porous and stable carrier system. The resulting rutin-loaded ZIF-8 nanoparticles have a particle size distribution below 100 nanometers. The encapsulation occurs via electrostatic interaction between the hydroxyl groups of rutin and the positively charged ZIF-8 framework, enabling enhanced drug stability and bioavailability. The composition remains stable under physiological pH but is configured to selectively release the encapsulated rutin in an acidic microenvironment, such as that found in degenerative regions of the brain associated with Parkinson’s disease. The invention also provides a method for preparing the nanoparticle composition.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF INVENTION

[0001] The present disclosure relates generally to the field of advanced materialsand chemical engineering. In particular, the present disclosure pertains tonanoparticle-based drug delivery for targeted neuroprotection against diseases.BACKGROUND

[0002] Parkinson's disease (PD) is a chronic and progressive neurodegenerativedisorder marked by the selective degeneration of dopaminergic neurons in thesubstantia nigra pars compacta. The consequent loss of dopamine severely affectsmotor coordination and manifests clinically as tremors, muscle rigidity,bradykinesia, and postural instability. In addition to motor deficits, PD alsopresents with non-motor symptoms such as sleep disturbances, depression, andcognitive impairment, which significantly impact the quality of life. Thepathology of PD is multifactorial, involving mitochondrial dysfunction, excessiveoxidative stress, protein aggregation, and neuroinflammation. Among these,oxidative stress plays a central role, contributing to neuronal damage via theaccumulation of reactive oxygen species (ROS) and lipid peroxidation.

[0003] Currently available therapies for Parkinson's disease, including levodopaand dopamine agonists, provide symptomatic relief but do not prevent or reversethe underlying neurodegeneration. Moreover, long-term administration of thesedrugs is often associated with fluctuating clinical responses, motor complicationssuch as dyskinesia, and systemic side effects. These limitations underscore theinadequacy of existing treatment modalities and the necessity of developingneuroprotective strategies capable of modifying disease progression.

[0004] Flavonoids, a class of naturally occurring polyphenolic compounds, haveattracted significant interest for their neuroprotective effects, primarily due to theirantioxidant and anti-inflammatory properties. Among them, rutin hasdemonstrated potent activity in mitigating oxidative stress and inflammation invarious experimental models of neurodegenerative disorders, includingParkinson's disease. Rutin is known to scavenge ROS, modulate inflammatorycytokines, and preserve neuronal integrity. However, despite its therapeuticpotential, the clinical application of rutin is severely restricted due to its pooraqueous solubility, low membrane permeability, and rapid metabolic degradation,leading to poor bioavailability and inadequate accumulation in the brain.

[0005] Another major challenge in the treatment of neurological diseases such asPD is the presence of the blood-brain barrier (BBB), which is a highly selectivephysiological barrier that prevents the entry of most pharmacological agents intothe central nervous system. The ability to deliver neuroprotective agents like rutinacross the BBB and into affected brain regions remains a major bottleneck intherapeutic development. Conventional delivery systems often result in systemicdistribution, off-target effects, and subtherapeutic drug levels in the brain.

[0006] Recent advancements in nanotechnology have opened new avenues forovercoming these challenges through the development of nanocarrier-based drugdelivery systems. Among these, metal-organic frameworks (MOFs) which are aclass of hybrid porous materials formed by coordination between metal ions andorganic ligands, have emerged as promising platforms for biomedicalapplications. Zeolitic imidazolate framework-8 (ZIF-8) exhibits several propertieshighly desirable for drug delivery, which include a large surface area, highporosity, tunable pore size, thermal and chemical stability, and pHresponsiveness.

[0007] ZIF-8 has been shown to remain stable under physiological pH (~7.4) butdisintegrates in mildly acidic environments (pH ~6.5 or lower), which arecommonly observed in diseased tissues such as inflamed or degenerating neuralregions. This pH-responsive degradation profile makes ZIF-8 a suitable candidatefor targeted drug release in pathological sites while minimizing premature drugleakage under normal conditions.

[0008] Hence, there is an urgent need for a nanoparticle-based drug deliverysystem that overcomes the limitations of rutin's solubility and bioavailability,enables efficient blood-brain barrier penetration, and facilitates pH-triggeredrelease in the neurodegenerative environment of Parkinson's disease, therebyoffering site-specific therapeutic intervention with minimized systemic sideeffects.OBJECTS OF THE PRESENT DISCLOSURE

[0009] Some of the objects of the present disclosure, which at least oneembodiment herein satisfies, are as listed herein below.

[0010] An object of the present disclosure is to provide a pH-responsivenanoparticle-based drug delivery composition for targeted neuroprotection inParkinson's disease.

[0011] Another object of the present disclosure is to provide a rutin-loadednanoparticulate formulation wherein rutin is encapsulated within zeoliticimidazolate framework-8 (ZIF-8) to overcome its poor aqueous solubility and lowbioavailability.

[0012] Yet another object of the present disclosure is to provide a drug deliverycomposition that is stable under physiological pH but undergoes controlleddisintegration under mildly acidic conditions, thereby enabling site-specificrelease of rutin in neurodegenerative regions of the brain.

[0013] Still another object of the present disclosure is to provide a nanoparticlebased system having a particle size distribution below 100 nanometers, therebyfacilitating crossing of the blood-brain barrier and enhancing brain-targeteddelivery.

[0014] An additional object of the present disclosure is to provide a compositionthat achieves rutin encapsulation via electrostatic interaction between the hydroxylgroups of rutin and the positively charged ZIF-8 network.

[0015] Yet another object of the present disclosure is to provide a method forpreparing the pH-responsive nanoparticle-based drug delivery composition usinga simple, room-temperature coordination reaction in methanol, followed bypurification and drying.

[0016] Still another object of the present disclosure is to provide aneuroprotective composition that is suitable for the treatment of Parkinson'sdisease and potentially other neurodegenerative conditions characterized bylocalized acidosis and oxidative stress.SUMMARY

[0017] This summary is provided to introduce a selection of concepts in asimplified form that is further described below in the detailed description section.This summary is not intended to identify key features or essential features of theclaimed subject matter, nor is it intended to be used as an aid in determining thescope of the claimed subject matter.

[0018] Aspects of the present disclosure relates to a pH-responsive nanoparticlebased drug delivery composition comprising rutin encapsulated within zeoliticimidazolate framework-8 (ZIF-8) for targeted neuroprotection in Parkinson'sdisease, and to a method for preparing said composition using a coordinationdriven self-assembly process under mild conditions.

[0019] Accordingly, in an aspect, the present disclosure provides a pHresponsive nanoparticle-based drug delivery composition for targetedneuroprotection in Parkinson's disease, comprising: a. rutin, a naturally occurringflavonoid compound; b. zeolitic imidazolate framework-8 (ZIF-8), formed bycoordination of zinc ions and 2-methylimidazole encapsulating the flavonoid;wherein said composition is configured to selectively release the encapsulatedrutin in an acidic microenvironment corresponding to degenerative regions of thebrain associated with Parkinson's disease and is stable at physiological pH.

[0020] In some embodiments, rutin is present in an amount ranging between 1%to 8% by weight of the total composition.

[0021] In some embodiments, the ZIF-8 nanoparticles have a particle sizedistribution below 100 nanometers.

[0022] In some embodiments, rutin is encapsulated within the ZIF-8 frameworkvia electrostatic interaction between the hydroxyl groups of rutin and thepositively charged zinc-imidazolate structure.

[0023] In some embodiments, pH-dependent release of rutin from the ZIF-8nanoparticles occurs at an acidic pH ranging between 6.0 to 6.8.

[0024] In some embodiments, the method for preparing a pH-responsivenanoparticle-based drug delivery composition comprises the steps of:a. dissolving rutin in methanol to obtain a clear drug solution;b. adding 2-methylimidazole to the drug solution of step (a) and stirring themixture until complete dissolution to obtain a homogeneous rutin-linkersolution;c. dissolving a zinc nitrate hexahydrate (Zn(NO3)2.6H2O) in methanol undermagnetic stirring to obtain a zinc ion solution;d. adding the zinc ion solution of step (c) gradually to the rutin-linkersolution of step (b) under constant magnetic stirring at a temperatureranging between 15-30°C, continuing the stirring for a time period of 1.5to 3 hours to allow self-assembly of rutin-loaded ZIF-8 nanoparticles;e. isolating the resulting nanoparticles by centrifugation, followed bywashing with methanol to remove unreacted components; andf. drying the purified nanoparticles at a temperature ranging between 35-40°C to obtain a dry powder formulation of the rutin-loaded ZIF-8composition.

[0025] In some embodiments, the zeolitic imidazolate framework-8 is formedusing 2-methylimidazole and zinc ions in a molar ratio of 2:1 to 200:1.

[0026] Various objects, features, aspects and advantages of the inventive subjectmatter will become more apparent from the following detailed description ofpreferred embodiments.BRIEF DESCRIPTION OF DRAWINGS

[0027] The accompanying drawings are included to provide a furtherunderstanding of the present disclosure and are incorporated in and constitute apart of this specification. The drawings illustrate exemplary embodiments of thepresent disclosure and, together with the description, serve to explain theprinciples of the present disclosure.

[0028] FIG.1 illustrates UV-Vis spectral analysis showing drug encapsulation.

[0029] FIG. 2 illustrates particle size of A) Blank ZIF-8 B) RUT@ZIF-8 andZeta potential of C) Blank ZIF-8 D) RUT@ZIF-8.

[0030] FIG. 3 illustrates FTIR spectrum of rutin, ZIF-8, and RUT@ZIF-8 usingthe KBr disc method.

[0031] FIG. 4 illustrates A) DSC thermograph and B) PXRD analysis of rutin,Blank ZIF-8 and RUT@ZIF-8.

[0032] FIG. 5 illustrates HR-TEM images of A)Blank ZIF-8, B)RUT@ZIF-8.

[0033] FIG. 6 illustrates HR-SEM images of A)Blank ZIF-8, B)RUT@ZIF-8.

[0034] FIG. 7 illustrates in vitro drug release profiles of RUT@ZIF-8 atphysiological and acidic conditions, compared with the release of free rutin.

[0035] FIG. 8 illustrates a comparison of the antioxidant activity of rutin,Rutin@ZIF-8 and ZIF-8 at different concentrations.

[0036] FIG. 9 illustrates the in vivo protocol for MPTP-induced parkinson'sdisease studies in zebrafish.

[0037] FIG. 10 illustrates behavioural tanks A) Open field tank, B) Novel divingtank, and C) Light and dark tank.

[0038] FIG. 11 illustrates the effect of rutin and Rutin@ZIF-8 treatment on theopen field test (OFT) in MPTP-treated zebrafish. A) represents track plots, B)Average speed, C) Distance travelled., followed by post-test Tukey for multiplecomparisons between groups.

[0039] FIG. 12 illustrates the effect of rutin and Rutin@ZIF-8 treatment onnovel diving tank test (NTT) in MPTP-treated zebrafish. A) represents track plots,B) depicts time spent in top zone (TSTZ), C) shows time spent in bottom zone(TSBZ), and D) depicts total entries in top zone (TETZ).

[0040] FIG. 13 illustrates the effect of rutin and Rutin@ZIF-8 treatment onLight and Dark Test (LDT) in MPTP-treated zebrafish. A) represents track plots,B) depicts time spent in light zone (TSLZ), C) shows time spent in dark zone(TSDZ), and D) depicts total entries in light zone (TELZ).

[0041] FIG. 14 illustrates the effect of rutin and RUT@ZIF-8 treatment ondopamine level.

[0042] FIG. 15 illustrates the effect of rutin and RUT@ZIF-8 treatment on lipidperoxide level.

[0043] FIG. 16 illustrates the effect of rutin and Rutin@ZIF-8 treatment onglutathione level.

[0044] FIG. 17 illustrates the effect of rutin and RUT@ZIF-8 treatment on TNFα level (GSH).

[0045] FIG. 18 illustrates the effect of rutin and RUT@ZIF-8 treatment onneuronal loss in MPTP-treated zebrafish. Photomicrographs of the posteriortuberculum region brain of Vehicle, MPTP, Rutin, ZIF-8, RUT@ZIF-8,MPTP+RUT, and MPTP+RUT@ZIF-8 treated groups are taken.DETAILED DESCRIPTION OF THE INVENTION

[0046] The following is a detailed description of embodiments of the disclosure.The embodiments are in such detail as to clearly communicate the disclosure.However, the amount of detail offered is not intended to limit the anticipatedvariations of embodiments; on the contrary, the intention is to cover allmodifications, equivalents, and alternatives falling within the spirit and scope ofthe present invention.

[0047] All publications herein are incorporated by reference to the same extentas if each individual publication or patent application were specifically andindividually indicated to be incorporated by reference. Where a definition or useof a term in an incorporated reference is inconsistent or contrary to the definitionof that term provided herein, the definition of that term provided herein applies,and the definition of that term in the reference does not apply.

[0048] Reference throughout this specification to "one embodiment" or "anembodiment" means that a particular feature, structure or characteristic describedin connection with the embodiment is included in at least one embodiment. Thus,the appearances of the phrases "in one embodiment" or "in an embodiment" invarious places throughout this specification are not necessarily all referring to thesame embodiment. Furthermore, the particular features, structures, orcharacteristics may be combined in any suitable manner in one or moreembodiments.

[0049] In some embodiments, numbers have been used for quantifying weightpercentages, ratios, and so forth, to describe and claim certain embodiments of theinvention and are to be understood as being modified in some instances by theterm "about." Accordingly, in some embodiments, the numerical parameters setforth in the written description and attached claims are approximations that canvary depending upon the desired properties sought to be obtained by a particularembodiment. In some embodiments, the numerical parameters should beconstrued in light of the number of reported significant digits and by applyingordinary rounding techniques. Notwithstanding that the numerical ranges andparameters setting forth the broad scope of some embodiments of the inventionare approximations, the numerical values set forth in the specific examples arereported as precisely as practicable. The numerical values presented in someembodiments of the invention may contain certain errors necessarily resultingfrom the standard deviation found in their respective testing measurements.

[0050] Various terms as used herein are shown below. To the extent a term usedin a claim is not defined below, it should be given the broadest definition personsin the pertinent art have given that term as reflected in printed publications andissued patents at the time of filing.

[0051] As used in the description herein and throughout the claims that follow,the meaning of "a," "an," and "the" includes plural reference unless the contextclearly dictates otherwise. Also, as used in the description herein, the meaning of"in" includes "in" and "on" unless the context clearly dictates otherwise.

[0052] Unless the context requires otherwise, throughout the specification whichfollow, the word "comprise" and variations thereof, such as, "comprises" and"comprising" are to be construed in an open, inclusive sense that is as "including,but not limited to."

[0053] The recitation of ranges of values herein is merely intended to serve as ashorthand method of referring individually to each separate value falling withinthe range. Unless otherwise indicated herein, each individual value is incorporatedinto the specification as if it were individually recited herein.

[0054] All methods described herein can be performed in any suitable orderunless otherwise indicated herein or otherwise clearly contradicted by context.The use of any and all examples, or exemplary language (e.g. "such as") providedwith respect to certain embodiments herein is intended merely to better illuminatethe invention and does not pose a limitation on the scope of the inventionotherwise claimed. No language in the specification should be construed asindicating any non-claimed element essential to the practice of the invention.

[0055] Groupings of alternative elements or embodiments of the inventiondisclosed herein are not to be construed as limitations. Each group member can bereferred to and claimed individually or in any combination with other members ofthe group or other elements found herein. One or more members of a group can beincluded in, or deleted from, a group for reasons of convenience and / orpatentability. When any such inclusion or deletion occurs, the specification isherein deemed to contain the group as modified.

[0056] The description that follows, and the embodiments described therein, isprovided by way of illustration of an example, or examples, of particularembodiments of the principles and aspects of the present invention. Theseexamples are provided for the purposes of explanation, and not of limitation, ofthose principles and of the disclosure.

[0057] It should also be appreciated that the present invention can beimplemented in numerous ways, including as a system, a method or a device. Inthis specification, these implementations, or any other form that the invention maytake, may be referred to as processes. In general, the order of the steps of thedisclosed processes may be altered within the scope of the invention.

[0058] The headings and abstract of the invention provided herein are forconvenience only and do not interpret the scope or meaning of the embodiments.

[0059] The following discussion provides many example embodiments of theinventive subject matter. Although each embodiment represents a singlecombination of inventive elements, the inventive subject matter is considered toinclude all possible combinations of the disclosed elements. Thus if oneembodiment comprises elements a, b, and c, and a second embodiment compriseselements b and d, then the inventive subject matter is also considered to includeother remaining combinations of a, b, c, or d, even if not explicitly disclosed.

[0060] For the purposes of the present disclosure, the term "rutin" refers to anaturally occurring bioflavonoid glycoside, chemically known as quercetin-3-O-rutinoside, commonly extracted from plant sources such as fruits, vegetables, andmedicinal plants such as buckwheat, citrus fruits, apples, and tea.

[0061] The term "biopolymeric carrier" refers to a naturally derived orsynthetically modified polymeric substance that forms the structural matrix of thenanoparticle. The carrier is responsible for encapsulating and protecting rutinduring formulation, storage, and delivery. Examples include chitosan, alginate,poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and otherbiodegradable or mucoadhesive polymers.

[0062] The term "encapsulation efficiency" refers to the percentage of the totalamount of rutin that is successfully entrapped or associated with the nanoparticlesrelative to the initial amount used in the formulation process. It is an importantparameter for evaluating the loading capacity and therapeutic potential of theformulation.

[0063] The present disclosure is further illustrated with reference to theaccompanying Figure and examples, which are intended to demonstrate thesynthesis, characterization, and functional evaluation of the rutin-basednanoparticles, and to facilitate understanding of their performance andapplications in relevant fields.

[0064] Aspects of the present disclosure relates to a pH-responsive nanoparticlebased drug delivery composition for targeted neuroprotection in Parkinson'sdisease. The composition comprises rutin with antioxidant and neuroprotectiveproperties, encapsulated within zeolitic imidazolate framework-8 (ZIF-8)nanoparticles providing a porous and stable carrier system. The encapsulationoccurs via electrostatic interaction between the hydroxyl groups of rutin and thepositively charged ZIF-8 framework, enabling enhanced drug stability andbioavailability. The composition remains stable under physiological pH but isconfigured to selectively release the encapsulated rutin in an acidicmicroenvironment, such as that found in degenerative regions of the brainassociated with Parkinson's disease. The invention also provides a method forpreparing the nanoparticle composition.

[0065] Accordingly, in an aspect, the present disclosure provides a pHresponsive nanoparticle-based drug delivery composition for targetedneuroprotection in Parkinson's disease, comprising: a. rutin, a naturally occurringflavonoid compound; b. zeolitic imidazolate framework-8 (ZIF-8), formed bycoordination of zinc ions and 2-methylimidazole encapsulating the flavonoid;wherein said composition is configured to selectively release the encapsulatedrutin in an acidic microenvironment corresponding to degenerative regions of thebrain associated with Parkinson's disease and is stable at physiological pH.

[0066] In some embodiments, rutin is present in an amount ranging between 1%to 8% by weight of the total composition. Preferably, the amount of rutin rangesbetween 1.5 % to 7.5 % by weight of the total composition, and most preferably inthe range between 2% to 6%.

[0067] In an exemplary embodiment, a loading of approximately 4% wasachieved with an entrapment efficiency of about 63%, indicating effective drugincorporation within the nanoparticulate system.

[0068] In some embodiments, the ZIF-8 nanoparticles have a particle sizedistribution below 100 nanometers. More particularly, blank ZIF-8 exhibited amean particle size of 71.5 ± 2.3 nm, and after rutin loading, RUT@ZIF-8 showedan increased size of 92.5 ± 2.1 nm, as measured by DLS. These sizes lie withinthe optimal range for blood-brain barrier (BBB) permeation, a key factor in thesuccessful delivery of neuroprotective agents.

[0069] In some embodiments, rutin is encapsulated within the ZIF-8 frameworkvia electrostatic interaction between the hydroxyl groups of rutin and thepositively charged zinc-imidazolate structure, as demonstrated by FTIR spectralanalysis.

[0070] In some embodiments, pH-dependent release of rutin from the ZIF-8nanoparticles occurs at an acidic pH ranging between 6.0 to 6.8.

[0071] In some embodiments, the ZIF-8 nanoparticles exhibit a polyhedralmorphology and uniform shape as seen in HR-TEM and SEM images. Upon rutinloading, the polyhedral shape was retained, although minor roughening andincreased internal contrast were observed, indicating internal drug entrapment.

[0072] In some embodiments, the method for preparing a pH-responsivenanoparticle-based drug delivery composition comprises the steps of:a. dissolving rutin in methanol to obtain a clear drug solution;b. adding 2-methylimidazole to the drug solution of step (a) and stirringthe mixture until complete dissolution to obtain a homogeneous rutin-linker solution;c. dissolving a zinc nitrate hexahydrate (Zn(NO3)2.6H2O) in methanolunder magnetic stirring to obtain a zinc ion solution;d. adding the zinc ion solution of step (c) gradually to the rutin-linkersolution of step (b) under constant magnetic stirring at a temperatureranging between 15-30°C, continuing the stirring for a time period of1.5 to 3 hours to allow self-assembly of rutin-loaded ZIF-8nanoparticles;e. isolating the resulting nanoparticles by centrifugation, followed bywashing with methanol to remove unreacted components; andf. drying the purified nanoparticles at a temperature ranging between 35-40°C to obtain a dry powder formulation of the rutin-loaded ZIF-8composition.

[0073] In some embodiments, the zeolitic imidazolate framework-8 is formedusing 2-methylimidazole and zinc ions in a molar ratio of 2:1 to 200:1. Mostpreferably, the molar ratio of 2-methylimidazole to zinc ions is 10:1 to 100:1.

[0074] In some embodiments, encapsulation of rutin within the ZIF-8framework improves its aqueous solubility and bioavailability.

[0075] In various embodiments, zebrafish models of Parkinson's disease(MPTP-induced) demonstrated that RUT@ZIF-8 provided greater neuroprotectioncompared to free RUT. Behavioural assays (open field, locomotor tests) showedstatistically significant improvement in movement metrics. Biochemical markers(GSH, TNF-α) and histopathology further supported reduced neuro inflammationand neuronal loss in the RUT@ZIF-8 treated group.

[0076] In still other embodiments, DPPH assay results revealed that RUT@ZIF8 preserved the antioxidant activity of rutin across all concentrations, indicatingthat encapsulation within ZIF-8 did not compromise rutin's bioactivity, a keyfactor in maintaining therapeutic effectiveness in oxidative-stress mediateddisorders like Parkinson's disease

[0077] While the foregoing description discloses various embodiments of theinvention, other and further embodiments of the invention may be devised withoutdeparting from the basic scope of the disclosure. The invention is not limited tothe described embodiments, versions or examples, which are included to enable aperson having ordinary skill in the art to make and use the invention whencombined with information and knowledge available to the person havingordinary skill in the art.EXAMPLES

[0078] The present invention is further explained in the form of the followingexamples. However, it is to be understood that the foregoing examples are merelyillustrative and are not to be taken as limitations upon the scope of the invention.Various changes and modifications to the disclosed embodiments will be apparentto those skilled in the art. Such changes and modifications may be made withoutdeparting from the scope of the invention.Example 1: Synthesis of Rutin-Loaded ZIF-8 Nanoparticles (RUT@ZIF-8)

[0079] RUT@ZIF-8 nanoparticles were synthesized using a one-pot solutionbased method. Initially, 7 mg of rutin was dissolved in methanol to form a clearsolution. To this, 0.645 g of 2-methylimidazole (2-MI) was added and stirred untilcomplete dissolution, yielding a homogeneous rutin-linker solution. Separately,0.234 g of zinc nitrate hexahydrate (Zn(NO3)2.6H2O) was dissolved in 25 mL ofmethanol to form a metal ion solution. This solution was added dropwise into therutin-linker mixture under continuous magnetic stirring at room temperature.Stirring was continued for an additional 2 hours to allow self-assembly of ZIF-8 inthe presence of rutin. The formation of a milky suspension confirmed nanoparticlegeneration. The resulting nanoparticles were collected by centrifugation, washedtwice with methanol to remove unreacted components, and dried at ambienttemperature to obtain a pale-yellow powder of RUT@ZIF-8.Example 2: Determination of Drug Loading and Entrapment Efficiency

[0080] The drug-loading capacity of the synthesized ZIF-8 nanoparticles wasassessed by calculating the percentage Drug Loading (%DL) and percentageEntrapment Efficiency (%EE) using the following standard formulas:Equation

[0081] To evaluate and confirm the encapsulation of RUT within the ZIF-8framework, a UV-Vis spectroscopic approach was adopted. The RUT@ZIF-8formulation was first analyzed without any pre-treatment. Then, RUT@ZIF-8particles were completely decomposed by treating them with 2 M hydrochloricacid (HCl), facilitating the complete release of RUT from the MOF matrix. Thisdegradation ensured disruption of the framework and maximized drug recovery.

[0082] Following degradation, the resulting solution was diluted appropriately toensure complete solubilization of the released RUT. The concentration of RUT inthe sample was then quantified spectrophotometrically using a UV-Visspectrophotometer. The absorbance was measured at the predetermined λmax ofRUT, and the concentration was calculated using a previously establishedstandard calibration curve of RUT in methanol. These values were subsequentlyused to compute the %DL and %EE, which are critical parameters reflecting theformulation's efficiency and capacity for therapeutic delivery.

[0083] The UV-Vis spectral analysis provided clear evidence of successfulinternal loading of RUT within the ZIF-8 framework. The RUT@ZIF-8formulation did not exhibit the typical absorption peak of free RUT, suggestingthe absence of surface-bound drug, as shown in FIG. 1. However, upon acidmediated breakdown of the structure, the characteristic peak of RUT reappearedin the UV-Vis spectrum. The calculated %DL was found to be 4%, while theentrapment efficiency (%EE) was determined to be 63%.Example 3: Particle Size and Surface Characterization

[0084] The mean particle size and polydispersity index (PDI) of both blank ZIF8 and RUT@ZIF-8 nanoparticles were determined using DLS analysis.Measurements were performed using a Delsa Nano Submicron Particle SizeAnalyzer (Beckman Coulter, USA). The formulations were appropriately dilutedwith deionized water to ensure optimal scattering intensity and analyzed at 25 ±0.5°C. All measurements, including particle size and polydispersity index (PDI),were performed in triplicate to ensure reproducibility and accuracy of the data.Results were expressed as the mean of three independent readings.

[0085] Dynamic Light Scattering (DLS) measurement results confirmed anarrow particle size distribution and good colloidal stability, enhanced further bydrug encapsulation. FIG. 2 depicts the particle size distribution and zeta potentialfor both blank ZIF-8 and RUT@ZIF-8.TableExample 4: FTIR, DSC, and PXRD Characterization

[0086] Fourier-transform infrared spectroscopy (FTIR) was performed usingKBr pellets to evaluate functional group interactions and confirm rutin loading.The disappearance of rutin's hydroxyl and aromatic stretching bands (e.g., 1658,1603 cm-1) in the RUT@ZIF-8 spectrum and retention of Zn-N stretching at ~422cm-1 indicated successful internal encapsulation.

[0087] Differential scanning calorimetry (DSC) was used to assess thermaltransitions, with samples scanned from 30°C to 300°C under nitrogenatmosphere. RUT showed an endothermic peak at ~110-120°C. This peakdisappeared in the RUT@ZIF-8 thermogram, suggesting molecular dispersion ofRUT within the MOF.

[0088] Powder X-ray diffraction (PXRD) was carried out over a 2θ range of 5°to 40° to examine crystallinity and phase changes before and after rutinencapsulation. RUT@ZIF-8 retained the crystalline peaks of ZIF-8 but lackedRUT's sharp peaks, confirming no surface crystallization. FIGs. 3 and 4 displaythe FTIR spectrum, DSC thermographs, and PXRD patterns.Example 5: Morphological Analysis Using HR-TEM and SEM

[0089] High-resolution transmission electron microscopy- Blank and RUTloaded ZIF-8 nanoparticles were dispersed in methanol and sonicated for 5-10minutes to achieve a uniform suspension. A drop of each suspension was carefullyplaced onto carbon-coated copper grids and dried at room temperature. Imagingwas conducted using a Tecnai G2 20 TWIN TEM (EDAX Inc., USA) operated atan accelerating voltage of 200kV. The analysis provided detailed insights intoparticle size, shape, and internal structural features, enabling comparativeevaluation of the blank and RUT@ZIF-8 formulations.

[0090] High-resolution scanning electron microscopy - SEM analysis wasconducted using a Nova Nano SEM 450 (FEI Company of USA (S.E.A.) PTE,LTD) equipped with Octane Plus and Hikari Pro detectors (EDAX Inc.). Samplesof blank and RUT@ZIF-8 nanoparticles were dispersed in methanol and sonicatedfor 5-10 minutes to obtain a uniform suspension. A drop of the suspension wasplaced onto a carbon-coated aluminium stub and dried under ambient conditions.The samples were then examined under SEM to assess surface morphology andtopography.

[0091] TEM and SEM images showed polyhedral morphology with preservedstructure post-encapsulation. RUT@ZIF-8 particles were slightly larger andexhibited internal density changes suggestive of internal loading. FIGs. 5 and 6show the HR-TEM and HR-SEM images, respectively.Example 6: In Vitro drug release profile by dialysis bag method

[0092] The in vitro drug release profile of the formulation was assessed usingthe dialysis bag diffusion technique to simulate controlled drug release underphysiological and pathological conditions. The study was conducted at twodistinct pH levels: pH 7.4, representing normal physiological conditions, and pH6.5, reflecting the acidic microenvironment typically associated with neuroinflammation in PD.

[0093] For the control experiment, free RUT (1 mg) was dissolved in 2 mL ofphosphate-buffered saline (PBS, pH 7.4) and enclosed in a pre-activated dialysismembrane. The dialysis bag was then immersed in 100 mL of PBS andmaintained at 37 ± 0.5°C under constant magnetic stirring to ensure uniformmixing and temperature stability. To assess the pH-sensitive release behaviour ofthe RUT@ZIF-8 formulation, two separate samples containing an equivalentamount of RUT were prepared in 2 mL of PBS and placed into individual dialysisbags. These were immersed in 100 mL of PBS maintained at pH 6.5 and 7.4,respectively, under the same controlled conditions. Aliquots of 3 mL werewithdrawn from the external medium at predefined time intervals, and eachwithdrawal was immediately replaced with an equal volume of pre-warmed freshPBS to maintain constant volume and sink conditions throughout the experiment.The collected samples were centrifuged to remove any undissolved particles, andthe supernatant was analyzed using a UV-Vis spectrophotometer. Theconcentrations of RUT were determined based on a pre-established calibrationcurve, allowing quantification of the drug release at each time point andcomparison between free drug and RUT@ZIF-8 formulations under both pHenvironments. This confirmed pH-responsive release behavior of the nanocarrier.FIG. 7 presents the drug release profile.Example 7: Antioxidant Activity by DPPH Assay

[0094] FIG. 8 and Table 1 represent a comparative analysis of the antioxidantactivity of RUT, blank ZIF-8, RUT@ZIF-8, and ascorbic acid (standard)measured by DPPH scavenging assay. Both RUT and RUT@ZIF-8 exhibiteddose-dependent antioxidant activity across concentrations ranging from 8 to 100μM. Encapsulation of RUT within the ZIF-8 framework did not significantlyaffect its antioxidant potential, as evidenced by comparable scavengingpercentages. At the highest concentration (100 μM), RUT demonstrated 87.55%DPPH scavenging activity, while RUT@ZIF-8 showed a similar activity of86.28%. Blank ZIF-8 exhibited modest antioxidant activity of 20.02% at 100 μM.Notably, RUT displayed greater antioxidant activity compared to ascorbic acid,which showed 38.66% scavenging at the same concentration.Table 1. %DPPH radical scavenging activity of rutin, RUT@ZIF-8,and ZIF-8Example 8: In Vivo Evaluation of RUT@ZIF-8 Nanoparticles in a ZebrafishModel of Parkinson's Disease.

[0095] In vivo studies were conducted using adult zebrafish (Danio rerio) toevaluate the neuroprotective potential of RUT@ZIF-8 in a Parkinson's disease(PD) model induced by MPTP. A total of 42 healthy zebrafish were divided intoseven groups (n = 6 per group) as detailed in Table 2. The treatment protocol,including acclimatization, dosing, and sacrifice, followed the timeline is outlinedin FIG. 9.Table 2: Experimental Grouping and Dosing

[0096] Intraperitoneal Administration Protocol- Intraperitoneal injectionswere performed using a 31G Hamilton microsyringe under brief anesthesiainduced via ice-cold water immersion. Each fish was placed ventral side up in asponge mold during injection. Formulations were administered at a volume notexceeding 10μL / g of body weight into the ventral midline region.

[0097] Behavioural Analysis-Three behavioural tests were conducted posttreatment using ANY-maze software with standardized environmental andrecording setups:

[0098] Open Field Test (OFT) (FIG. 10A): Conducted in 15 x 15 x 15 cmtanks (3L water, 28±0.5°C). Locomotion was recorded for 5 minutes after 2-minute acclimatization. Parameters: total distance travelled and average speed.

[0099] Novel Tank Diving Test (NTT) (FIG. 10B): Performed in 28 x 20 x 20cm tanks. Zones were demarcated. Parameters: Time Spent in Top Zone (TSTZ),Bottom Zone (TSBZ), and Total Entries in Top Zone (TETZ).

[00100] Light-Dark Test (LDT) (FIG. 10C): Conducted in a 30 x 16 x 15 cmtank divided into light / dark zones. Parameters: Time in Light Zone (TSLZ), DarkZone (TSDZ), and Total Entries into Light Zone (TELZ).

[00101] Behavioural Results-MPTP treatment significantly impaired locomotoractivity, reduced TSTZ and TSLZ, and increased anxiety-like behaviours.RUT@ZIF-8 treatment significantly improved behavioural metrics compared toMPTP alone and RUT treatment, restoring values toward control levels across alltests (p < 0.01 or better) as demonstrated in the FIGs. 11-13. Data are expressed inmean ± SD, and statistical analysis performed by one-way ANOVA, followed bypost-test Tukey for multiple comparisons between groups.

[00102] Biochemical Analysis: Following behavioral tests, fish were euthanized,and brain tissues were harvested for biochemical estimations:a. Dopamine (FIG. 14): Estimated via iodine oxidation. MPTP reduceddopamine levels (p < 0.001); RUT and RUT@ZIF-8 restored levels(RUT@ZIF-8 > RUT).b. Lipid Peroxidation (LPO) (FIG. 15): MPTP elevated MDA levels (p <0.001); treatments reversed oxidative stress.c. Glutathione (GSH) (FIG. 16): MPTP depleted GSH (p < 0.001);RUT@ZIF-8 showed superior restoration over RUT.d. TNF-α (FIG. 17): MPTP increased inflammatory cytokine levels;treatments decreased TNF-α (RUT@ZIF-8 > RUT).

[00103] Histopathology- Brains were fixed in formalin, paraffin-embedded, andstained with H&E. FIG. 18 illustrates that MPTP induced neuronal loss andvacuolization. RUT@ZIF-8 preserved cytoarchitecture significantly better thanRUT. Data expressed as mean ± SD. One-way ANOVA with Tukey's post hoctest was applied. Significance: p < 0.05.

[00104] This in vivo study demonstrates that RUT@ZIF-8 effectively amelioratesbehavioural, biochemical, and histopathological alterations in MPTP-induced PDzebrafish. Compared to free RUT, RUT@ZIF-8 offers superior neuroprotection,antioxidant action, and anti-inflammatory effects, validating its potential fortargeted PD therapy.ADVANTAGES OF THE PRESENT DISCLOSURE

[00105] The present disclosure offers the significant advantage of enablingtargeted neuroprotection in Parkinson's disease through a pH-responsive drugdelivery system.

[00106] The system releases rutin specifically in acidic microenvironmentsassociated with neuronal degeneration, while remaining stable at physiologicalpH.

[00107] The encapsulation of rutin within zeolitic imidazolate framework-8 (ZIF8) nanoparticles enhances the aqueous solubility, chemical stability, andpharmacokinetic profile of rutin.

[00108] The particle size of the formulated Rutin@ZIF-8 nanoparticles facilitatesefficient crossing of the blood-brain barrier, thereby enabling site-specificdelivery of the neuroprotective agent directly to affected regions of the brain.

[00109] The use of ZIF-8 as a biocompatible metal-organic framework providesmultiple benefits, including high surface area, porosity, and pH-responsivedisintegration behavior, making it an ideal nanocarrier for brain-targetedtherapies.

[00110] The electrostatic interaction between the hydroxyl groups of rutin and thepositively charged framework of ZIF-8 ensures efficient drug loading andstructural integrity of the encapsulated formulation.

[00111] The formulation exhibits controlled and sustained drug release underacidic pH conditions, as confirmed by in vitro release studies, thereby minimizingpremature release and reducing systemic toxicity.

[00112] The synthesis method using methanol as the solvent is facile,reproducible, and carried out at room temperature, making it industrially scalableand cost-effective without the need for complex processing or high-temperatureconditions.

[00113] The composition retains the polyhedral morphology and crystallinity ofZIF-8 post-encapsulation, as confirmed by transmission electron microscopy(TEM) and powder X-ray diffraction (PXRD), which supports the nanoparticle'srobustness and uniformity.

[00114] In vivo studies conducted using a zebrafish model of Parkinson's diseasedemonstrate that the disclosed composition has the potential to amelioratebehavioral, biochemical, and histological markers of neurodegeneration, therebysupporting its therapeutic promise.

[00115] The present disclosure overall discloses targeted, and biocompatiblestrategy for treating Parkinson's disease and potentially other neurodegenerativedisorders, by overcoming conventional barriers related to drug solubility, delivery,and localization.

Claims

1. A pH-responsive nanoparticle-based drug delivery composition for targeted neuroprotection in Parkinson's disease, comprising: a. rutin, a naturally occurring flavonoid compound; b. zeolitic imidazolate framework-8 (ZIF-8), formed by coordination of zinc ions and 2-methylimidazole encapsulating the flavonoid; wherein said composition is configured to selectively release the encapsulated rutin in an acidic microenvironment corresponding to degenerative regions of the brain associated with Parkinson's disease and is stable at physiological pH.

2. The composition as claimed in claim 1,wherein the rutin is present in an amount ranging between 1% to 8% by weight of the total composition.

3. The composition as claimed in claim 1, wherein the ZIF-8 nanoparticles have a particle size distribution below 100 nanometers.

4. The composition as claimed in claim 1, wherein the rutin is encapsulated within the ZIF-8 framework via electrostatic interaction between the hydroxyl groups of rutin and the positively charged zinc-imidazolate structure.

5. The composition as claimed in any one of the preceding claims, wherein the pH-dependent release of rutin from the ZIF-8 nanoparticles occurs at an acidic pH ranging between 6.0 to 6.

8.

6. The method for preparing a pH-responsive nanoparticle-based drug delivery composition as claimed in claim 1, comprising the steps of: a. dissolving rutin in methanol to obtain a clear drug solution; b. adding 2-methylimidazole to the drug solution of step (a) and stirring the mixture until complete dissolution to obtain a homogeneous rutin-linker solution; c. dissolving a zinc nitrate hexahydrate (Zn(NO3)2.6H2O) in methanol under magnetic stirring to obtain a zinc ion solution; d. adding the zinc ion solution of step (c) gradually to the rutin-linker solution of step (b) under constant magnetic stirring at a temperature ranging between 15-30°C, continuing the stirring for a time period of 1.5 to 3 hours to allow self-assembly of rutin-loaded ZIF-8 nanoparticles; e. isolating the resulting nanoparticles by centrifugation, followed by washing with methanol to remove unreacted components; and f. drying the purified nanoparticles at a temperature ranging between 35- 40°C to obtain a dry powder formulation of the rutin-loaded ZIF-8 composition.

7. The method as claimed in claim 6, wherein the zeolitic imidazolate framework-8 is formed using 2-methylimidazole and zinc ions in a molar ratio of 2:1 to 200:1.